Revolution Medicines appoints Lorence Kim to Board, replacing Neil Exter

Revolution Medicines, Inc.

Dr. Kim appointed Class I director effective July 12, 2022, filling vacancy from Exter's resignation.
Determined independent; qualifies as audit committee financial expert; served on Audit Committee.
Venture Partner at Third Rock Ventures, former CFO of Moderna, and ex-Managing Director at Goldman Sachs.
Received initial option for 36,800 shares and 10,500 RSUs under Non-Employee Director Compensation Program.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Neil Exter

Director

RVMD · Revolution Medicines, Inc.

Effective: 2022-07-12
Successor: Lorence Kim
Filed: July 13, 2022, 7:59 PM ET

Dr. Kim was appointed to fill the vacancy on the Board created by the resignation of Neil Exter, who resigned from the Board, effective July 12, 2022.

Appointed

Lorence Kim

Class I Director

RVMD · Revolution Medicines, Inc.

Effective: 2022-07-12
Filed: July 13, 2022, 7:59 PM ET

On July 9, 2022, the Board of Directors (“Board”) of Revolution Medicines, Inc. (the “Company”) appointed Lorence Kim, M.D., as a member of the Board, effective July 12, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Exter resigned as Director at Revolution Medicines, Inc..

Action: resigned
Role: Director

Exact text from the filing

Dr. Kim was appointed to fill the vacancy on the Board created by the resignation of Neil Exter, who resigned from the Board, effective July 12, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lorence Kim was appointed as Class I Director at Revolution Medicines, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On July 9, 2022, the Board of Directors (“Board”) of Revolution Medicines, Inc. (the “Company”) appointed Lorence Kim, M.D., as a member of the Board, effective July 12, 2022.

View on SEC.gov

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-192292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.